Søren Kragh Moestrup
Fondatore presso DeLiver Pharma ApS
Profilo
Søren Kragh Moestrup is the founder of Proteopharma AS, which was founded in 2000, and Cytoguide ApS, which was founded in 2007.
At Cytoguide ApS, he held the title of Chief Executive Officer from 2007 to 2014.
Dr. Moestrup is also the founder of DeLiver Pharma ApS.
Currently, he is the Director at Affinicon ApS since 2013.
In the past, he worked at the University of Oxford as a Principal from 1994 to 1995, and at the University of Aarhus as a Member from 1999 to 2010.
Posizioni attive di Søren Kragh Moestrup
Società | Posizione | Inizio |
---|---|---|
Affinicon ApS
Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Direttore/Membro del Consiglio | 24/07/2013 |
DeLiver Pharma ApS
DeLiver Pharma ApS Pharmaceuticals: MajorHealth Technology DeLiver Pharma ApS manufactures pharmaceutical products. The firm carries on business with medical development and any related business. The company was founded on March 9, 2018 and is headquartered in Odense, Denmark. | Fondatore | - |
Precedenti posizioni note di Søren Kragh Moestrup
Società | Posizione | Fine |
---|---|---|
University of Oxford | Corporate Officer/Principal | 01/01/1995 |
Proteopharma AS
Proteopharma AS Pharmaceuticals: MajorHealth Technology Part of 5AM Venture Management LLC, Proteopharma AS is a Danish pharmaceutical company that manufactures pharmaceuticals. The company is based in Aarhus, Denmark. The company was founded by Niels Jonas Heilskov Graversen and Søren Kragh Moestrup. Proteopharma was acquired by Borean Pharma ApS on February 16, 2004. | Fondatore | - |
University of Aarhus | Corporate Officer/Principal | - |
Cytoguide ApS
Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | Amministratore Delegato | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 4 |
---|---|
Cytoguide ApS
Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | Health Technology |
Proteopharma AS
Proteopharma AS Pharmaceuticals: MajorHealth Technology Part of 5AM Venture Management LLC, Proteopharma AS is a Danish pharmaceutical company that manufactures pharmaceuticals. The company is based in Aarhus, Denmark. The company was founded by Niels Jonas Heilskov Graversen and Søren Kragh Moestrup. Proteopharma was acquired by Borean Pharma ApS on February 16, 2004. | Health Technology |
Affinicon ApS
Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Health Technology |
DeLiver Pharma ApS
DeLiver Pharma ApS Pharmaceuticals: MajorHealth Technology DeLiver Pharma ApS manufactures pharmaceutical products. The firm carries on business with medical development and any related business. The company was founded on March 9, 2018 and is headquartered in Odense, Denmark. | Health Technology |
- Borsa valori
- Insiders
- Søren Kragh Moestrup